Brief: Theravet Broadens Portfolio With Innovative Line Of Biological Bone Grafts
07/02/2022 06:32
Feb 7 (Reuters) - Theravet SA ALVET.PA :
* THERAVET BROADENS ITS BONE SUBSTITUTES PORTFOLIO WITH AN
INNOVATIVE LINE OF BIOLOGICAL BONE GRAFTS
* THERAVET BONE SUBSTITUTES' OFFER NOW ONE OF MOST
COMPREHENSIVE
ON VETERINARY MARKET
Source text for Eikon: ID:nBw3f7QWMa
Further company coverage: ALVET.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Theravet SA
See all newsBrief: Theravet Announces Setting Up Of An Equity-Linked Financing Facility
Brief: TheraVet Provides Update On 2023 Half-Year Development And Portfolio Strategy
Brief: Theravet Announces 300% Increase In Participating Centers In Its Osteosarcoma Program
Brief: Theravet End-Dec Cash Position Of EUR 3.19 Mln
Brief: Theravet Signs New Distribution Agreement For Its Biocera-Vet With Elvetis